QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module IX Signal Management in EudraVigilance and the EU Regulatory Network

Test your understanding of the concepts covered by GVP Module IX: Signal Management in EudraVigilance and the EU Regulatory Network.

Question 1 of 10Pass mark: 80%

Question 1 of 10 An apparent increase in reporting is observed after a change in case coding and a major increase in product exposure. What should the assessment team do first?

Conclude that the incidence of the adverse reaction has increased. Assess data quality, coding, duplicates, reporting behaviour and exposure before interpreting the pattern as a change in risk. Exclude all cases reported after the coding change without review. Request an immediate product-information restriction solely on the basis of the reporting increase.

Question 2 of 10 Which sequence best represents the conceptual EU regulatory-network signal-management pathway?

Assessment, detection, confirmation, implementation, validation, prioritisation Detection, validation, confirmation, prioritisation, assessment, recommendation or action, follow-up Confirmation, implementation, detection, assessment, prioritisation, reporting Prioritisation, detection, regulatory action, validation, confirmation, follow-up

Question 3 of 10 What is the principal governance function of EPITT?

To replace the scientific assessment dossier To record and track pharmacovigilance issues, including status, ownership and procedural progress To determine causality automatically from EudraVigilance data To serve as the MAH's internal safety database

Question 4 of 10 An MAH receives a request for additional analyses from the regulatory network. What is the most appropriate response?

Treat it as an administrative request and provide only the minimum data requested without context. Provide complete, accurate and appropriately contextualised information, including relevant limitations, and assess any implications for the company's system. Decline to respond because the MAH cannot influence the regulator's scientific conclusion. Provide only information that supports the company's existing assessment.

Question 5 of 10 Why is product-specific MAH context important when interpreting an EudraVigilance signal?

EudraVigilance data are never useful without replacing them with company data. Product-specific information such as exposure, formulation, indication, follow-up cases and risk-minimisation measures may materially affect interpretation. MAH context is relevant only for commercial planning and not for safety assessment. Product-specific context should be excluded to preserve regulatory neutrality.

Question 6 of 10 An MAH's regulatory-affairs team receives a PRAC recommendation but does not communicate it to pharmacovigilance because the recommendation is considered an external regulatory matter. What is the key concern?

The company may have an interface failure preventing regulatory safety information from entering the pharmacovigilance assessment process. The company has appropriately separated regulatory and pharmacovigilance responsibilities. The recommendation cannot affect the MAH unless it is issued directly to the company's QPPV. Only NCAs are responsible for assessing the relevance of published PRAC recommendations.

Question 7 of 10 Which statement best characterises transparency in the EU signal-management system?

Transparency requires publication of every intermediate scientific discussion. Transparency includes publication of relevant PRAC recommendations and related information, while still allowing appropriate management of intermediate discussions. Transparency is incompatible with regulatory confidentiality and is therefore not part of signal management. Only MAHs, and not healthcare professionals or patients, benefit from published recommendations.

Question 8 of 10 What is the correct relationship between signal management and the RMP?

The RMP is separate from signal management and should only be updated at fixed intervals. A regulatory conclusion may affect the safety specification, pharmacovigilance activities and risk-minimisation measures, so its implications should be integrated into the RMP lifecycle. Only a product-information change can justify consideration of an RMP update. The regulator's assessment removes the MAH's responsibility to evaluate RMP implications.

Question 9 of 10 How does signal confirmation differ from proof of causality?

Confirmation establishes that the issue is sufficiently credible for formal signal management, while causality remains subject to assessment. Confirmation is performed only after regulatory action has been completed. Confirmation means that the association has been demonstrated beyond reasonable scientific doubt. Confirmation concerns data formatting only and has no scientific component.

Question 10 of 10 Following implementation of a new risk-minimisation measure, what is the most mature next step?

Close the safety issue permanently once the measure is approved. Assess whether the measure achieved its intended purpose using an appropriate effectiveness-monitoring approach where required. Assume effectiveness because the measure was recommended by PRAC. Stop routine pharmacovigilance for the affected risk.

Knowledge Assessment: GVP Module IX Signal Management in EudraVigilance and the EU Regulatory Network

Cookie Settings